Duromine vs GLP-1 medicines: two very different approaches

What is the main difference between Duromine and GLP-1 medicines?

Duromine contains phentermine, a stimulant that suppresses appetite through the nervous system and is registered for short courses only. GLP-1 medicines copy a hormone the gut releases after eating, reduce hunger and slow stomach emptying, and are registered for ongoing weight management. Mechanism, schedule, course length and evidence all differ.

The practical differences follow from that. A Duromine course is measured in weeks, a GLP-1 plan in months. Duromine's side effects are stimulant-type, insomnia and a faster heart rate among them, while GLP-1 side effects are mostly digestive. The average weight loss recorded in trials sits in a different range for each class too.

Both are scheduled medicines with real exclusion lists, and both only work alongside changes to eating and activity. Every Duromine vs GLP-1 decision runs through those exclusion lists before any trial number matters.

What is Duromine and how does it work?

Duromine is phentermine, a stimulant appetite suppressant chemically related to amphetamine. In South Africa it comes as 15 mg and 30 mg capsules taken once a day in the early morning, registered as a short-term addition to a supervised weight-loss programme for people with a BMI of 30 or more.

The capsule holds phentermine in a slow-release resin that lets the dose out over 10 to 14 hours, which is why one morning capsule lasts the day. Taking it later in the day is discouraged because the stimulant effect can keep you awake at night.

Phentermine works through the hypothalamus, the brain's appetite centre, mainly by increasing noradrenaline and dopamine activity. Along with reduced hunger comes a stimulant load on the heart: a faster pulse, stronger contraction and a rise in blood pressure, which shapes who can take it safely.

The registered use is specific. A doctor first rules out medical causes of weight gain, confirms the BMI threshold or the presence of weight-related risk factors, and pairs the capsule with diet, activity and behaviour changes. Duromine on its own, without that programme around it, is not how the registration reads.

What are GLP-1 medicines?

GLP-1 medicines copy glucagon-like peptide-1, a hormone the gut releases after eating. They reduce hunger, slow stomach emptying and steady blood sugar. In South Africa the class includes semaglutide (Ozempic and Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda), given as weekly or daily injections under the skin.

Registrations differ by brand. Wegovy (semaglutide 2.4 mg) launched here in August 2025, registered for chronic weight management. Mounjaro arrived in December 2024 for type 2 diabetes and added a weight-management registration in October 2025. Saxenda, injected daily, was the first GLP-1 registered here specifically for weight management. Ozempic is registered for type 2 diabetes, not weight loss.

The full local picture, including availability and how treatment is structured, is in our guide to GLP-1 in South Africa, and the mechanism is unpacked in what semaglutide is and how it works.

How are Duromine and GLP-1 medicines scheduled in South Africa?

Duromine is a Schedule 5 medicine and the GLP-1 medicines are Schedule 4. South African schedules tighten as the number rises, and phentermine's higher schedule reflects its stimulant nature and potential for dependence. In practice both need the same route: a doctor's assessment and authorisation, then dispensing by a licensed pharmacy.

Schedule 5 also brings tighter dispensing controls and record-keeping at the pharmacy, which fits how the medicine is meant to be used: a defined course with a review at the end, rather than an open-ended supply.

Neither medicine may lawfully be sold over the counter, through social media sellers or by import websites. A listing that offers either without a doctor involved is a warning sign, whatever the price and whichever class it claims to be.

How long can you take Duromine?

Short courses only. The South African professional information recommends medical review after a defined course, which ideally should not exceed three months, and registers Duromine as short-term monotherapy only. GLP-1 medicines are registered the opposite way, for ongoing treatment with regular review.

The time limit is not paperwork. Older appetite suppressants used beyond three months were linked to a rare but serious lung condition, primary pulmonary hypertension, and phentermine's stimulant load on the heart plus its dependence potential add further reasons to keep courses short and reviewed.

South African practice does not always match the label. A South African Medical Journal analysis of private-sector claims from 2015 to 2019 found that about a quarter of 3,361 phentermine users stayed on it longer than 12 weeks. The average course, roughly two months, sat inside the limit, but the long tail is exactly what the review requirement exists to catch.

GLP-1 treatment runs on the opposite logic. Obesity is treated as a long-term condition, the major trials ran for 56 to 72 weeks, and weight tends to return when treatment stops early. What happens after the injections is covered in keeping weight off after GLP-1 treatment, and the reasoning behind treating obesity as a chronic condition is on our obesity page.

Which produces more weight loss in trials?

No head-to-head trial has compared them, so only separate records exist. Pooled short-term trials of phentermine found an average of 3.6 kg more weight loss than placebo. GLP-1 trials running a year or longer recorded average losses of 8% to 20.2% of body weight, depending on the molecule. Individual results vary.

The phentermine figure comes from a pooled analysis of six trials lasting 2 to 24 weeks. A longer study over 36 weeks recorded an average of 12.2 kg lost with continuous phentermine against 4.8 kg with placebo. For a course of three months or less, that is a real and useful result.

The GLP-1 record is longer and larger. Liraglutide 3.0 mg averaged 8% of body weight, 8.4 kg against 2.8 kg with placebo, over 56 weeks in the SCALE trial. Semaglutide 2.4 mg averaged 14.9% over 68 weeks in STEP 1. In SURMOUNT-5, the head-to-head between the two newest molecules, tirzepatide averaged 20.2% against semaglutide's 13.7% over 72 weeks. Individual results vary in every one of those studies.

Reading the two records against each other needs care, which is why a bare Duromine vs GLP-1 number line misleads. The phentermine trials were short, small by modern standards and measured kilograms; the GLP-1 trials were long, large and measured percentages, with structured diet and activity support built in. The records describe two different jobs, a short push and a sustained treatment, and the right option is decided by a doctor on assessment.

Duromine vs GLP-1 at a glance

Individual results vary. The trial figures are averages from different studies with different lengths and designs, not a prediction for any one person and not a direct contest between the classes.

What are the side effects of Duromine?

The common ones are stimulant effects: insomnia, restlessness, nervousness, tremor, dizziness, headache and dry mouth, along with a faster pulse, palpitations and raised blood pressure. Nausea, cramps and changed bowel habits occur too. Rarely, mood changes or psychotic episodes have been reported.

The exclusion list is long, with the heart at its centre. Duromine must not be used by people with heart disease, rhythm problems, arterial hypertension, pulmonary hypertension or advanced arteriosclerosis, nor with hyperthyroidism, glaucoma or poorly controlled epilepsy. A history of depression, anorexia nervosa or another psychiatric condition rules it out, as does a history of alcohol or drug dependence. It is not used in pregnancy or while breastfeeding, or within 14 days of MAOI antidepressants, and combinations with some other antidepressants need careful medical review.

Two warnings deserve their own lines. New or worsening breathlessness or chest pain on Duromine means stop and seek medical care immediately. And because the medicine can affect alertness, take care with driving until you know how it affects you; alcohol makes the dizziness worse and is best avoided during a course.

How do GLP-1 side effects compare?

GLP-1 side effects sit in the gut rather than the nervous system: nausea, vomiting, diarrhoea, constipation and stomach discomfort, concentrated in the early months and around dose increases. They do not cause the wakefulness or jitteriness of a stimulant, and the digestive effects usually settle with time and careful dose steps.

Serious risks are rare but defined. Pancreatitis can occur, so severe, persistent stomach pain means seek medical care immediately. Gallbladder problems appear more often with rapid weight loss. GLP-1 medicines are not used in pregnancy or while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or MEN2.

Managing the digestive phase is mostly practical, smaller meals and enough fluids among the tactics, and our guide to managing GLP-1 side effects covers it in detail. The two exclusion lists barely overlap, which is one reason the same patient can be unsuitable for one class and well suited to the other.

How do the costs compare?

The shapes differ more than the monthly figures. A Duromine course is short, so spending stops when the course does. GLP-1 treatment is ongoing, so its monthly cost repeats for as long as treatment lasts, and published GLP-1 prices are also considerably higher month for month.

Spotlight reported in February 2026 that maintenance doses of semaglutide and tirzepatide generally cost between R3,000 and R6,000 a month in South Africa, sometimes more at the highest strengths, while pharmacy listings for Duromine sit well below that band. The regulated price of any registered medicine can be checked on the Department of Health's Medicine Price Registry at mpr.gov.za. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

Medical aid rarely helps with either when the reason is weight: obesity is not a Prescribed Minimum Benefit condition, and most schemes exclude weight-loss medicine from standard cover. The full cost picture for the injectable class, including the costs that sit around the medicine itself, is in GLP-1 treatment costs in South Africa.

Can you take Duromine and a GLP-1 together?

No. The Duromine professional information states it should not be combined with other appetite suppressants, and the safety of phentermine alongside any other weight-loss medicine has not been established. One medicine at a time, changed under a doctor's management, is the only safe pattern.

Sequential use does happen in practice. A person who completed Duromine courses years ago may later be assessed for GLP-1 treatment, and someone unsuited to one class may be assessed for the other. Each step needs its own screening, because the exclusion lists differ so widely.

What should not happen is self-directed stacking or bridging, finishing one medicine on a Friday and starting the other on Monday without medical input. The gap between medicines, the starting dose and the screening all need a doctor's decision, the same as any first start.

How does a doctor choose between Duromine and a GLP-1?

The Duromine vs GLP-1 choice is made on your health picture, not on trial averages. Heart health, blood pressure, mental-health history, sleep, dependence history, pregnancy plans, treatment goals and budget each push toward or away from one class, and several of them rule one option out entirely.

Cardiovascular status decides more than anything else. High blood pressure or heart disease closes the Duromine route, because phentermine raises pulse, the force of each heartbeat and blood pressure. GLP-1 medicines work through appetite hormones rather than stimulation, so a person with cardiac risk and a person without can get opposite answers.

Horizon matters as much. A defined three-month push suits some situations; treating obesity as the long-term condition it is points toward the class registered for ongoing use. Sleep problems, anxiety or a history of depression weigh against a stimulant. Reluctance about injections weighs the other way. These are screening questions, and each has a factual answer in your history.

Both routes start with a doctor: screening, baseline health checks and a doctor-confirmed treatment plan, with the medicine dispensed by a licensed pharmacy. The right option is decided by a doctor on assessment.

Frequently asked questions